iBio (IBIO) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of iBio (NASDAQ: IBIO) in the last few weeks:

• 9/21/2026 – iBio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/17/2026 – iBio is now covered by HC Wainwright. They set a “buy” rating and a $7.00 price target on the stock.
• 9/17/2026 – iBio is now covered by HC Wainwright. They set a “buy” rating and a $7.00 price target on the stock.
• 9/13/2026 – iBio was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/5/2026 – iBio was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/23/2026 – iBio was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/15/2026 – iBio was upgraded by Wall Street Zen from “sell” to “hold”.

iBio, Inc is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify antibody candidates and optimize their properties for potential use in cancer, autoimmune, inflammatory and fibrotic diseases.

iBio’s technology platform is based in part on the antibody-discovery capabilities obtained through its acquisition of RubrYc Therapeutics. The platform is designed to support target selection, antibody generation and optimization, with an emphasis on identifying antibodies that bind specific disease-related epitopes.